Neurological syndromes associated with COVID-19: a multicenter study in Brazil

Abstract Background Neurological manifestations associated with COVID-19 remain partially described, mainly in low- and middle-income countries where diagnostic tools are limited. To address this, we assembled medical centers in Brazil with the goal of describing neurological syndromes associated wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Aline de Moura Brasil Matos, Andre Borges Ferreira Gomes, Fernanda Martins Maia Carvalho, Francisco Tomaz Meneses de Oliveira, Lohana Santana Almeida da Silva, Flavia Esper Dahy, Joao Victor Luisi de Moura, Marcela Vieira Freire, Jose Ernesto Vidal, Rosa Maria Nascimento Marcusso, Jerusa Smid, Victor Rebelo Procaci, Rodrigo Meireles Massaud, Felipe Von Glehn, Jorge Casseb, Camila Malta Romano, Augusto Cesar Penalva de Oliveira, on behalf of NeurocovBR study group
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-025-10504-6
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Neurological manifestations associated with COVID-19 remain partially described, mainly in low- and middle-income countries where diagnostic tools are limited. To address this, we assembled medical centers in Brazil with the goal of describing neurological syndromes associated with COVID-19 during the first wave of the pandemic. Methods From June 1st, 2020 to June 1st, 2021, non-consecutive adult patients with new onset of six neurological syndromes up to 60 days after confirmed COVID-19 were included. Data were compiled from four tertiary centers and compared with general local COVID-19 data, as well as with a previous cohort focused on vascular syndrome. Results 197 patients were included, presenting with vascular syndromes (81), encephalopathy (68), encephalitis (19), Guillain-Barré syndrome (13), other neuropathies (12), and myelitis (4). The incidence curve of neurocovid mirrored that of COVID-19. Neurological syndromes were present regardless of COVID-19 severity. The median time from COVID-19 to onset of neurological symptoms was 14 days, suggesting a post-infectious immune-mediated mechanism. Patients were 10 times more likely to die (χ2 (1) = 356.55, p < 0.01, OR = 10.89) and 38 times more likely to be hospitalized than other COVID-19 patients (χ2 (1) = 1167.9, p < 0.01, OR = 38.22). Those developing vascular syndromes patients were 3 times more likely to require ICU (χ2 (1) = 37.12, p < 0.01, OR = 3.78) and 4 times more likely to die (χ2 (1) = 58.808, p < 0.01, OR = 4.73) than patients with vascular syndromes due to different etiologies. Conclusions Our study corroborates the association of neurological syndromes with COVID-19. The incidence correlated with local waves of COVID-19, and patients with neurocovid exhibited a higher susceptibility to adverse outcomes compared to other COVID-19 patients. Among all neurological syndromes, vascular syndromes were the most common, and their severity surpassed that of vascular syndromes not attributed to COVID-19.
ISSN:1471-2334